Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Expression of the Fas antigen on primary human leukemia cells (1995)
    Springer
    Annals of hematology 70 (1995), S. 15-17 
    Details
    ISSN: 1432-0584
    Keywords: Fas antigen ; Apoptosis ; Leukemia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The antigen defined by the monoclonal antibody anti-Fas can mediate apoptosis, is associated with the receptor for tumor necrosis factor, and is expressed on a limited number of human tissues. In this study we analyzed the expression of Fas on primary human leukemic cells and on mononuclear cells from other hematologic disorders. A total of 95 samples of blood or bone marrow were studied by indirect immunofluorescence. These samples included the normal controls, 47 cases of acute myelogenous leukemia (AML), 11 cases of acute lymphoblastic leukemia (ALL), 21 cases of leukemic lymphoma, seven cases of chronic myelogenous leukemia (CML), five cases of plasma cell leukemia or multiple myeloma, and five cases of myelodysplastic or myeloproliferative syndromes. Normal controls were negative without exception. Among AML, 13/47 cases (28%) were positive; among ALL, 1/11 cases (9%) was positive; among leukemic lymphomas, 3/21 cases (14%) were positive. In a case of plasma cell leukemia which strongly expressed the Fas antigen, we demonstrated that the antibody mediates cell lysis, which was synergistically enhanced by the addition of rabbit complement. In patients with AML, Fas positivity had no obvious clinical relevance. Taken together, our results show that approximately 30% of cases of AML and occasionally other leukemias express the Fas antigens, whereas normal controls are negative in our test system. These findings may be useful in the treatment of refractory leukemias or may permit the purging of autologous transplants.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01715376
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Lymphokine activated killer cells (1989)
    Springer
    Annals of hematology 59 (1989), S. 375-384 
    Details
    ISSN: 1432-0584
    Keywords: Lymphokine activated killer cells ; Interleukin-2
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Various subpopulations of human leukocytes may be induced by lymphokines to exert cytotoxic activity. In man major histocompatibility complex non-restricted tumor cell lysis by interleukin-2 (IL-2) induced peripheral blood lymphocytes is attributed mainly to natural killer cells. These T cell receptor negative large granular lymphocytes are called lymphokine activated killer (LAK) cells. In order to explore the potential of LAK cells in tumor therapy, several clinical studies have been conducted, using IL-2 alone or in combination with ex vivo IL-2-activated peripheral blood lymphocytes. Objective responses have reproducibly been achieved only in renal cell carcinoma and malignant melanoma and were associated with considerable toxicity. In view of restricted efficacy and increasing doubts as to whether LAK cells indeed account for the in vivo observed responses, more recent strategies focus on tumor antigen specific cytotoxic T cells or tumor infiltrating lymphocytes. Successful translation of this approach into clinical practice, however, may be dependend on some basic problems of tumor immunology to be solved which were thought to be by-passed by the LAK cell approach.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00321208
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Expression of the Fas antigen on primary human leukemia cells (1995)
    Springer
    Annals of hematology 70 (1995), S. 15-17 
    Details
    ISSN: 1432-0584
    Keywords: Key words Fas antigen ; Apoptosis ; Leukemia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary  The antigen defined by the monoclonal antibody anti-Fas can mediate apoptosis, is associated with the receptor for tumor necrosis factor, and is expressed on a limited number of human tissues. In this study we analyzed the expression of Fas on primary human leukemic cells and on mononuclear cells from other hematologic disorders. A total of 95 samples of blood or bone marrow were studied by indirect immunofluorescence. These samples included the normal controls, 47 cases of acute myelogenous leukemia (AML), 11 cases of acute lymphoblastic leukemia (ALL), 21 cases of leukemic lymphoma, seven cases of chronic myelogenous leukemia (CML), five cases of plasma cell leukemia or multiple myeloma, and five cases of myelodysplastic or myeloproliferative syndromes. Normal controls were negative without exception. Among AML, 13/47 cases (28%) were positive; among ALL, 1/11 cases (9%) was positive; among leukemic lymphomas, 3/21 cases (14%) were positive. In a case of plasma cell leukemia which strongly expressed the Fas antigen, we demonstrated that the antibody mediates cell lysis, which was synergistically enhanced by the addition of rabbit complement. In patients with AML, Fas positivity had no obvious clinical relevance. Taken together, our results show that approximately 30% of cases of AML and occasionally other leukemias express the Fas antigens, whereas normal controls are negative in our test system. These findings may be useful in the treatment of refractory leukemias or may permit the purging of autologous transplants.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01715376
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Leukocytoclastic vasculitis and long-term remission in a patient with secondary AML and post-remission treatment with low-dose interleukin-2 (1995)
    Springer
    Annals of hematology 70 (1995), S. 227-230 
    Details
    ISSN: 1432-0584
    Keywords: Interleukin-2 ; Acute myeloid leukemia ; Leukocytoclastic vasculitis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Interleukin-2 (IL-2) has been licensed for the treatment of renal cell carcinoma and is currently being evaluated as a therapeutic agent in hematological malignancies. It is associated with a variety of side effects due to induction of a nonspecific inflammatory response. However, phenomena of autoimmunity have also been reported. Here we describe a patient with secondary acute myeloid leukemia who developed a leukocytoclastic vasculitis during long-term post-remission treatment with very low doses of IL-2.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01700380
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Polypeptides controlling hematopoietic cell development and activation (1989)
    Springer
    Annals of hematology 58 (1989), S. 117-128 
    Details
    ISSN: 1432-0584
    Keywords: Hematopoietic growth factors ; In vitro effects ; Progenitor cells ; Mature end-cells
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Recombinant DNA technology has been central in answering some of the most relevant questions in the research of regulation of the functional status of hematopoietic progenitor cells and their progeny. This leading article will focuse on recent results that have emerged from studies utilizing recombinant molecules that control hematopoietic blood cell development and activation. The following features will be detailed: The molecular and biological characteristics and biochemistry of hematopoietic growth factors, synergizing factors and releasing factors, their role in the regulation of hematopoiesis and activation of normal and leukemic cells, their cellular sources, and regulation of production.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00320430
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Polypeptides controlling hematopoietic blood cell development and activation (1989)
    Springer
    Annals of hematology 58 (1989), S. 173-179 
    Details
    ISSN: 1432-0584
    Keywords: Hematopoietic growth factors ; Clinical application
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Colony-stimulating factors (CSFs) have entered the clinical arena. Several investigators have explored, in first clinical phase I studies, different routes of administration to define the optimum biological dose, maximum tolerated dose, toxicity, and pharmacokinetics of these reagents. It has been demonstrated that recombinant human (rh) granulocyte-macrophage CSF (GM-CSF) and granulocyte CSF (G-CSF) can be safely administered over a broad dose range to increase number of circulating granulocytes in man. More recently, GM-CSF and G-CSF have been involved in phase Ib/II studies to assess the granulopoietic responses of patients with granulocytopenia due to various underlying disease states including myelodysplastic syndrome, aplastic anemia, cyclic neutropenia, Kostmann's syndrome, and the acquired immuno-deficiency syndrome. Both factors were also investigated with respect to their potential to prevent chemotherapy induced granulocytopenia or to accelerate recovery from that condition. The short-term effects of rh GM-CSF after autologous bone marrow transplantation for various solid tumors and lymphoid malignancies were assessed as well. In this article we will focus on recent results that have emerged from in vivo studies utilizing CSFs.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00320769
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Untersuchung der DNS-abhängigen RNS-Polymerase aus menschlichen Leukocyten in einem einfachen zellfreien System (1973)
    Springer
    Journal of molecular medicine 51 (1973), S. 730-734 
    Details
    ISSN: 1432-1440
    Keywords: Leukocytes ; Leukemia ; RNA-polymerase ; RNA-metabolism ; Leukocyten ; Leukämie ; RNS-Polymerase ; RNS-Stoffwechsel
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Lymphocyten und Leukocyten (Lymphocyten + Granulocyten) werden aus 10–40 ml heparinisiertem Venenblut isoliert, homogenisiert und 15 min bei 1000 g zentrifugiert. In dem aus Zellkernen und Kerntrümmern bestehenden Sediment lassen sich nach Resuspension ca. 70% der DNA-abhängigen RNS-Polymerase-Aktivität des Homogenats nachweisen. Die Reaktion ist von zugesetzter DNS und der Gegenwart aller vier Ribonucleosid-Triphosphate abhängig. Bei chronisch lymphatischer Leukämie, chronisch myeloischer Leukämie und Morbus Hodgkin findet sich unter diesen Bedingungen eine höhere spezifische Aktivität der DNS-abhängigen RNS-Polymerase als bei Normalpersonen.
    Notes: Summary Lymphocytes and leukocytes (lymphocytes + granulocytes), isolated from 10–40 ml of heparinized venous blood, are homogenized, and centrifuged for 15 min at 1000 g. The resuspended pellet, consisting of nuclei and nuclear debris, exhibits ca. 70% of the DNA-depenent RNA polymerase activity of the homogenate. The reaction depends on added DNA template and the presence of all four ribonucleoside triphosphates. In chronic lymphatic leukaemia, chronic myelocytic leukemia, and Hodgkin's disease, the activity of the DNA-dependent RNA polymerase is higher than in normal controls.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01468365
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Freie und matrizen-gebundene RNS-Polymerase in normalen und leukämischen Lymphocyten (1976)
    Springer
    Journal of molecular medicine 54 (1976), S. 235-237 
    Details
    ISSN: 1432-1440
    Keywords: DNA-dependent RNA-polymerase B ; Functional properties and regulation ; Leukemia ; DNS-abhängige RNS-Polymerase B ; Funktionelle Differenzierung und Regulation ; Leukaemie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Es werden die spezifischen Aktivitäten von zwei funktionell unterschiedlichen Fraktionen der α-Amanitin-inhibierbaren DNS-abhängigen RNS-Polymerase in Zellkernen normaler menschlicher Lymphocyten (NL) sowie von Lymphocyten bei chronischer lymphatischer Leukämie (CLL) bestimmt. Die Aktivität der „freien“ RNS-Polymerase bei CLL beträgt 0,133 gegenüber 0,209 pMol (3H)-UMP/106 Zellen in normalen Lymphocyten. Die Aktivitäten der „gebundenen“ Enzyme liegen bei 0,139 (CLL) bzw. 0,132 pMol (3H)-UMP/106 Zellen (NL). Durch 400 ng/ml Rifamycin AF/013 wird das „freie“ Enzym in NL und CLL völlig inhibiiert, während das „gebundene“ Enzym noch 70% seiner Aktivität aufweist. Da „freie“ Enzym in CLL-Lymphocyten wird durch 1,0 ng/ml α-Amanitin zu 50% inhibitiert, während dieses Enzym in NL sowie die „gebundenen“ Enzyme in NL und CLL zu mehr als 90% inaktiviert werden.
    Notes: Summary Specific activities are determined of two functional fractions of α-amanitin sensitive DNA-dependent RNA polymerases in nuclei from human normal and chronic lymphocytic leukemia lymphocytes. Specific activity of “free” RNA polymerase in CLL corresponds to 0.133 pmoles (3H)-UMP/106 cells as compared to 0.209 in normals. Activities of the “engaged” enzymes are 0.139 in CLL and 0.132 in normals. “Free” enzymes in NL and CLL are completely inhibited by 400 ng/ml Rifamycin AF/013, while the “engaged” enzymes exhibit 70% of their original activity. 1.0 ng/ml α-amanitin suppress 50% of the activity of the “free” enzyme in CLL. The “free” enzyme in NL and the “engaged” enzymes in NL and CLL do not show any residual activity in the presence of 1.0 ng/ml α-amanitin.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01469131
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...